Biotest AG. (4/13/17). "Press Release: Biotest Informs about Limited Availability of Albumin". Dreieich.

	Organisation	Biotest AG
	Group	Grifols (Group)
	Product	albumin, human
	Person	Buttkereit, Monika (Biotest 201308 Head of Investor Relations)
	Person 2	Neumüller, Dirk (Biotest 201608 Public Relations)

- Due to an equipment failure the availability of albumin is currently limited

- Consequences on sales and annual results are currently not assessable

Today, Biotest has started to inform its customers about an expected albumin supply shortage within the coming months. This is due to an equipment failure in the production of an albumin intermediate. The equipment failure has already been fixed.

In accordance with the relevant authorities, Biotest decided today that all batches which have been produced in the affected equipment and have already been supplied, must not be used until the issue is clarified.

Additional necessary analyses are currently conducted. We expect results within the next four weeks. Biotest will take further steps on the basis of these analysis data. The impact on sales and annual results for the Biotest Group are only assessable afterwards.

About Human Albumin

Albumin is used in particular in intensive care medicine and acute care. Patients with extensive blood or fluid loss, due to burns among other things, have too little of the important proteins in their blood. This protein loss is compensated by administering Albumin. Albumin is also used for volume replacement in cases of blood poisoning. Unlike synthetically manufactured drugs, Albumin produced from human plasma offers particularly good tolerability. It is also the most important protein carrier in the blood for binding and removing (harmful) substances from the vascular system.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

Record changed: 2023-06-05